Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis

BACKGROUND: Multiple myeloma is a bone marrow‐based hematological malignancy accounting for approximately two per cent of cancers. First‐line treatment for transplant‐ineligible individuals consists of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T). However, acces...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cochrane Database Syst Rev
Glavni autori: Piechotta, Vanessa, Jakob, Tina, Langer, Peter, Monsef, Ina, Scheid, Christof, Estcourt, Lise J, Ocheni, Sunday, Theurich, Sebastian, Kuhr, Kathrin, Scheckel, Benjamin, Adams, Anne, Skoetz, Nicole
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2019
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6876545/
https://ncbi.nlm.nih.gov/pubmed/31765002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013487
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items